Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients (NCT05068531)
A Prospective Observational Cohort Study for Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients Undergoing Systemic Chemotherapy and Liver Resection With Curative Intent
🩺 Plain-English Summary (8th-Grade Level)
In North America, colorectal cancer patients with resectable liver-restricted metastases (mCRC-LR) are treated with approximately 6 months of preoperative systemic multi-agent chemotherapy. Actuarial data however supports that approximately 20% of mCRC-LR patients can be cured without as much systemic chemotherapy. Prospective phase II-III trials also support that awaiting recurrence to initiate further metastases-targeted or systemic treatment may provide patients with longer overall survival while avoiding toxicities in those without recurrence.
Who can join: Review the eligibility criteria below.
Location: Centre hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Centre hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 890-8000
Email: wiam.belkaid.chum@ssss.gouv.qc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer Metastatic
- Assessing How Normal Variations in CT Scanning Affects Its Interpretation — New York, New York
- A Phase 1b Study of WU-NK-101 in Combination With Cetuximab — San Francisco, California
- Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) — Los Angeles, California
- BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases — La Jolla, California
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis — Lake Success, New York
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases — New York, New York
Explore by condition: All Colorectal Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.